Biomarkers and artificial intelligence open new avenues for anticipating Alzheimer’s progr... 21/09/2026 Healthcare Drug discovery Personalized medicine In Spain, nearly one million people were living with dementia in 2025, according to estimates from Alzheimer Europe... Partners - ADmit Therapeutics
Biomarkers and artificial intelligence open new avenues for anticipating Alzheimer’s progr... 21/09/2026 ADmit Therapeutics In Spain, nearly one million people were living with dementia in 2025, according to estimates from Alzheimer Europe... AseBio - ADmit Therapeutics
Biotechnology is driving earlier and more personalised approaches to sepsis 13/09/2026 Healthcare In vitro diagnostics Personalized medicine Together with clinical experts, researchers and our partner Viva In Vitro Diagnostics, we analyse the main challenges in... AseBio - VIVA IN VITRO
Sepsis causes 11 million deaths every year, while new biomarkers are paving the way for a ... 13/09/2026 VIVA IN VITRO In Spain, around 50,000 people are affected by sepsis each year and approximately 17,000 die, highlighting the... AseBio - VIVA IN VITRO
Viva in Vitro and Vall d’Hebron will investigate the potential of functional NLRP3 biomark... 07/09/2026 Healthcare Drug discovery Personalized medicine The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of... Partners - VIVA IN VITRO
iPremom raises €15m to transform pregnancy care with molecular diagnostics 03/09/2026 Healthcare Access to innovation Personalized medicine iPremom, a molecular diagnostics company dedicated to the earliest prediction of pregnancy complications, has raised... Partners - Asabys Partners
Biometriks Health, Ubikare, vitalera, Athlon y Cuico Health selected to present at the Hea... 01/09/2026 Healthcare Access to innovation Personalized medicine Partners - UBIKARE
An Opportunity to Transform Research on Rare Diseases in Europe 24/07/2026 Healthcare Rare diseases Personalized medicine Between 27 and 36 million people in the European Union live with one of the 6,000 to 8,000 known rare diseases. Partners - GENESIS Biomed
Illumina drives genomic education through G4US, a program that brings students and researc... 22/07/2026 Healthcare Personalized medicine Talento The Genomics for Universities Students (G4US) program is our commitment to supporting universities across Europe with... Partners - Illumina
#BIOSPAIN2026 | Encapsulation technologies: Driving the next generation of therapies 22/07/2026 Healthcare Personalized medicine International BioSpain The future of medicine will depend not only on discovering new drugs, but also on developing technologies capable of... AseBio
